ST. LOUIS, Aug. 9 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. today reported record revenue for the quarter ended June 30, 2007. Revenue for the second quarter increased 105% to $7.8 million, compared with $3.8 million in revenue in the second quarter of 2006. Revenue from Niobe(TM) systems sales grew 102% to $5.8 million compared with $2.9 million in the 2006 second quarter, reflecting an increase in the number of systems sold during the quarter and an increase in the average selling price. Disposables, services and accessories revenue also set a new record, increasing to $2.1 million in the second quarter of 2007 from $1.0 million in the second quarter of 2006.
After adjustment for one order where the underlying project has been moved to the hospital’s subsequent budget year and for systems recognized to revenue in the second quarter, at June 30, 2007, purchase orders and other commitments for Stereotaxis Niobe(TM) systems totaled approximately $55 million, with $13.6 million added during the most recent quarter. The Company does not include orders for disposables, service or other accessories in its backlog data. These commitments are subject to contingencies that are outside the Company’s control and may be revised, modified or cancelled. There were more than 250 accounts in the Company’s mid to late stage pipeline, or sales funnel, and another 300 accounts in the early stages of development.
“Our second quarter results demonstrate continued excellent market momentum for our Niobe system as well as increasing strong demand as demonstrated by our record backlog,” said Bevil Hogg, Chief Executive Officer of Stereotaxis. “During the quarter we recognized five new systems, including three in the U.S., bringing the total number of Niobe systems shipped worldwide to 77. We continue to focus our worldwide sales efforts on the approximately 300 electrophysiology labs within hospitals that annually initiate plans to build, refurbish or upgrade facilities. Our efforts have led to another quarter of significantly increased year over year revenue, record operating gross margin, strong orders and record backlog, with little measurable impact from the increased competitive environment. We remain on track to achieve our targeted 90% to 100% year over year revenue increase in 2007.”
“During the quarter, we believe the installed base continued to increase its use of the Niobe system. The total number of procedures performed on Niobe systems is now believed to be in excess of 9,000. The number of Atrial Fibrillation procedures has surpassed 1,000. We believe that the launch of our Odyssey Network Solution during the fourth quarter, the anticipated launch of an irrigated catheter in Europe by early fourth quarter, and our exemplary safety record will play major roles in expanding our strong market leadership position,” added Mr. Hogg.
Gross profit totaled $3.5 million in the second quarter of 2007, 44.6% of revenue. Included in the 2007 gross profit was a $1.9 million impairment charge related to legacy Niobe I systems, which were replaced with the current Niobe systems in 2004. Excluding the impairment charge, the gross profit margin in the recent second quarter was 68.4%. This compares with gross profit of $1.6 million, or 42.8% in the second quarter of 2006. The improvement in the gross profit margin in 2007 is primarily the result of a 21% year over year increase in the average selling price of Niobe systems.
Total operating expenses increased 22% to $18.9 million in the quarter, compared with $15.5 million in the second quarter of 2006. The increase was driven by higher research and development expenses related to Odyssey development, platform expansion, and new device introductions, as well as increased sales and marketing expense.
The Company reported a net loss for the second quarter of 2007 of $15.0 million, or $(0.42) per share. This compares to a net loss of $13.6 million, or $(0.41) per share, in the second quarter of 2006. The weighted average shares for the recent second quarter were 36.2 million compared with 33.2 million in the second quarter of last year. The increase in weighted average shares reflected the issuance of 1.9 million shares in a sale of common stock in a registered direct offering completed in March 2007 pursuant to a shelf registration as well as the exercise of warrants in 2006.
For the first six months of 2007, revenue totaled $17.0 million compared with revenue of $5.5 million for the first six months of 2006. The Company reported a net loss of $25.5 million through the recent first six month period versus a net loss of $28.2 million for the first six months of 2006. On a per share basis, the first six months net loss in 2007 was $(0.72) compared with $(0.88) in the comparable period of 2006.
Cash and investments at June 30, 2007 totaled $32.8 million, compared with $37.0 million at December 31, 2007. Total debt was $2.5 million.
2007 Guidance
The Company reiterated its revenue guidance for 2007, confirming that it expects revenue to be 90% to 100% higher than the $27.2 million generated in fiscal 2006. The Company’s sales cycle, common to sales of capital equipment to hospitals, is relatively long and is subject to lumpiness from quarter to quarter, reflecting hospital budget decisions and revisions to installation schedules.
“At the beginning of the year, we estimated that our revenue for 2007 would be less back end loaded than 2006 and our results are consistent with our expectation, putting us significantly ahead of the same point one year ago,” said Mr. Hogg. “We remain focused on successfully executing our growth plans, including our initial launch into the interventional cardiology markets and remain very confident of our prospects over the short and long term.”
Conference Call Information
The Company has scheduled a conference call for 8:30 a.m. Eastern Standard Time today to discuss its financial results for the second quarter. To access the conference call, please dial (800) 240-7305. International participants can call (303) 262-2130. An audio replay of the call will be available for seven 7 days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11094027#. The call will also be available on the Internet live and for 90 days thereafter at the following URL: http://www.videonewswire.com/event.asp?id=41368
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
STEREOTAXIS, INC. STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2007 2006 2007 2006 Revenue Systems revenue $5,771,587 $2,860,101 $12,979,029 $3,842,698 Disposables, service and accessories revenue 2,063,652 953,919 4,017,165 1,703,114 Total revenue 7,835,239 3,814,020 16,996,194 5,545,812 Cost of revenue Inventory impairment 1,870,653 - 1,870,653 - Other cost of revenue 2,472,678 2,182,425 5,723,025 3,414,416 Total cost of revenue 4,343,331 2,182,425 7,593,678 3,414,416 Gross margin 3,491,908 1,631,595 9,402,516 2,131,396 Operating expenses: Research and development 7,090,948 5,539,759 12,785,639 11,669,627 General and administration 4,848,888 4,286,408 9,791,830 8,306,152 Sales and marketing 6,986,475 5,715,392 13,066,396 10,588,776 Total operating expenses 18,926,311 15,541,559 35,643,865 30,564,555 Operating loss (15,434,403) (13,909,964) (26,241,349) (28,433,159) Interest income 491,103 629,839 873,558 1,110,832 Interest expense (62,616) (330,404) (142,232) (883,506) Net loss $(15,005,916) $(13,610,529) (25,510,023) $(28,205,833) Net loss per common share: Basic and diluted $(0.42) $(0.41) $(0.72) $(0.88) Weighted average shares used in computing net loss per common share: Basic and diluted 36,152,659 33,221,875 35,285,931 32,187,229 STEREOTAXIS, INC. BALANCE SHEETS June 30, December 31, 2007 2006 (Unaudited) Assets Current Assets: Cash and cash equivalents $26,058,239 $15,210,493 Short-term investments 6,761,286 21,773,288 Accounts receivable, net of allowance of $117,963 and $90,716 in 2007 and 2006, respectively 15,365,238 15,280,628 Current portion of long-term receivables - 163,362 Inventories 8,689,523 8,285,825 Prepaid expenses and other current assets 2,249,335 2,580,773 Total current assets 59,123,621 63,294,369 Property and equipment, net 6,297,530 4,130,295 Intangible assets, net 1,477,778 1,544,444 Long-term receivables 379,486 - Other assets 322,374 321,552 Total assets $67,600,789 $69,290,660 Liabilities and stockholders’ equity Current liabilities: Current maturities of long-term debt $1,000,000 $1,666,666 Accounts payable 5,412,376 5,555,121 Accrued liabilities 8,208,366 10,025,231 Deferred contract revenue 7,060,774 5,663,553 Total current liabilities 21,681,516 22,910,571 Long term debt, less current maturities 1,472,222 305,556 Long term deferred contract revenue 1,031,406 1,220,174 Other liabilities 448,915 65,367 Stockholders’ equity: Preferred stock, par value $0.001; 10,000,000 shares authorized at 2007 and 2006; none outstanding at 2007 and 2006 - - Common stock, par value $0.001; 100,000,000 shares authorized at 2007 and 2006; 36,927,201 and 34,755,397 issued at 2007 and 2006, respectively 36,927 34,755 Additional paid-in capital 272,596,239 248,908,918 Treasury stock, 40,151 shares at 2007 and 2006 (205,999) (205,999) Accumulated deficit (229,460,862) (203,950,839) Accumulated other comprehensive gain/(loss) 425 2,157 Total stockholders’ equity 42,966,730 44,788,992 Total liabilities and stockholders’ equity $67,600,789 $69,290,660
Stereotaxis, Inc.
CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis,+1-314-678-6105, or Investor Contact - Douglas Sherk, or Jenifer Kirtland,+1-415-896-6820, or Jennifer Beugelmans, +1-646-201-5447, or Media Contact- Steve DiMattia, +1-646-201-5445, all of EVC Group, Inc.
Web site: http://www.stereotaxis.com/
